Since individuals who carry the CCR5-Δ32 mutation are physiologically normal and CCR5 overexpression is found in various malignancies, recent interest has focused on retasking CCR5 antagonists developed for HIV treatment for cancer and cancer-related diseases. Here, CCR5 is linked to cancer.